Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 6, 2025
Reporting Period: First Quarter ended March 31, 2025
Context: This filing announces the issuance of a press release regarding Q1 2025 financial results and schedules a conference call for May 6, 2025.
Key Financial Metrics
The provided text is a cover report referencing a press release (Exhibit 99.1) but does not contain specific financial data tables or figures within the body of this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in the source text provided. Investors must refer to the referenced press release (Exhibit 99.1) for these details.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior comparable period. It only confirms that results for the quarter ended March 31, 2025, have been issued.
Guidance, Outlook, and Risks
Management Commentary: The Company is hosting a conference call and webcast to present business and financial results. The webcast will be archived for 60 days.
Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties, including those detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (filed February 25, 2025).
Legal Disclaimer: Information furnished under Item 2.02 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific Q1 2025 revenue, net income, and cash position figures.
- Verify the Company's updated guidance and outlook provided during the May 6, 2025 conference call.
- Consult the Form 10-K filed on February 25, 2025, for a comprehensive list of risk factors referenced in this 8-K.
- Confirm the availability of the archived webcast on the Company's website for detailed management commentary.